Asset
Cinacalcet hydrochloride
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00135304 | phase4 | completed | 2005-08-01 | 2006-10-01 | Amgen | ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism |
| NCT00261950 | phase2 | completed | 2006-05-01 | 2011-05-01 | Amgen | Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease |
| NCT00132431 | phase4 | completed | 2004-07-01 | — | Amgen | START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism |
| NCT01439867 | phase2 | terminated | 2012-06-22 | 2016-06-03 | Amgen | Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 021688 | NDA | AMGEN INC |
Marketed products (3)
- SENSIPAR
- SENSIPAR
- SENSIPAR